DR. JOSE FRANCISCO LEIS MD
Prescription History 1790793271
Internal Medicine - Hematology & Oncology in Scottsdale, AZ


Quality Rating: 78.58 out of 100 score

NPI Status: Active since August 03, 2006

Contact Information

13400 E SHEA BLVD
SCOTTSDALE, AZ
ZIP 85259
Phone: (480) 301-8000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOSE FRANCISCO LEIS MD, an active Hematology & Oncology specialist practicing in Scottsdale, AZ. Our medical registry currently tracks 12 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 456 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 143 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 143
30-Day Fills 266.0
Days Supply 7,962
AZ State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,138
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 495.8% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,433.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.01

State Avg Cost Per Claim

$24.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 30
30-Day Fills 41.0
Days Supply 1,230
AZ State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills118.0
Peer Average Days Supply3,525
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $260.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.68

State Avg Cost Per Claim

$16.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
AZ State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.8
Peer Average Days Supply504
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.8% more claims than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $273,658.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,898.18

State Avg Cost Per Claim

$14,078.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 390
AZ State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills126.3
Peer Average Days Supply3,676
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.0% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,319.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$522.83

State Avg Cost Per Claim

$954.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gleevec

Generic Formulation: Imatinib MesylateSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
AZ State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply611
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $139,900.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,772.24

State Avg Cost Per Claim

$10,075.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 72
30-Day Fills 72.0
Days Supply 2,040
AZ State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply808
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 157.1% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,090,551.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,146.55

State Avg Cost Per Claim

$14,703.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Jaypirca

Generic Formulation: PirtobrutinibSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
AZ State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$22,740.42

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 60
AZ State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply117
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $117.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.75

State Avg Cost Per Claim

$10.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 28
30-Day Fills 46.0
Days Supply 1,308
AZ State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,030
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.32

State Avg Cost Per Claim

$6.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 77
AZ State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.5
Peer Average Days Supply446
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $90.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.23

State Avg Cost Per Claim

$19.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 66
30-Day Fills 79.8
Days Supply 2,190
AZ State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply405
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 164.0% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $291.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.41

State Avg Cost Per Claim

$6.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematopoietic Cell Transplantation and Cellular Therapy
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 764
AZ State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply724
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235,902.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,737.13

State Avg Cost Per Claim

$8,675.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOSE FRANCISCO LEIS MD provides transparency into local medical care patterns within Scottsdale, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.